相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam
Pham Thi Thu Thuy et al.
ANTIVIRAL THERAPY (2018)
Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial
Anne L. H. Ovrehus et al.
JOURNAL OF HEPATOLOGY (2018)
Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection
Mostafa Yakoot et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2018)
Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis
Hussien Ahmed et al.
JOURNAL OF INFECTION AND PUBLIC HEALTH (2018)
A Bayesian response-adaptive trial in tuberculosis: The endTB trial
Matteo Cellamare et al.
CLINICAL TRIALS (2017)
Short-Duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir for Hepatitis C: A Randomized Trial
Eric Lawitz et al.
HEPATOLOGY (2017)
Reinventing HCV Treatment: Past and Future Perspectives
Wendy Carter et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Factorial versus multi-arm multi-stage designs for clinical trials with multiple treatments
Thomas Jaki et al.
STATISTICS IN MEDICINE (2017)
Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study)
Mark S. Sulkowski et al.
LIVER INTERNATIONAL (2017)
Response Tailored Protocol Versus the Fixed 12 Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial
Mostafa Yakoot et al.
EBIOMEDICINE (2017)
Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naive or Experienced Patients
Mindie H. Nguyen et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
Design and monitoring of multi-arm multi-stage clinical trials
Pranab Ghosh et al.
BIOMETRICS (2017)
Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong
C. L. Lai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response
Scott M. Berry et al.
CLINICAL TRIALS (2016)
Potential market size and impact of hepatitis C treatment in low- and middle-income countries
M. E. Woode et al.
JOURNAL OF VIRAL HEPATITIS (2016)
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study
George Lau et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection
Edward J. Gane et al.
GASTROENTEROLOGY (2015)
Modelling hepatitis C therapy-predicting effects of treatment
Alan S. Perelson et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Tuberculosis treatment and management-an update on treatment regimens, trials, new drugs, and adjunct therapies
Alimuddin Zumla et al.
LANCET RESPIRATORY MEDICINE (2015)
Global Distribution and Prevalence of Hepatitis C Virus Genotypes
Jane P. Messina et al.
HEPATOLOGY (2015)
The utility of Bayesian predictive probabilities for interim monitoring of clinical trials
Benjamin R. Saville et al.
CLINICAL TRIALS (2014)
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Mark S. Sulkowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products
Meg A. Gamalo et al.
PHARMACEUTICAL STATISTICS (2014)
Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?
James M. S. Wason et al.
TRIALS (2014)
Early stopping rules in oncology: Considerations for clinicians
Som D. Mukherjee et al.
EUROPEAN JOURNAL OF CANCER (2011)
Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit
Patrick Royston et al.
TRIALS (2011)
The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report
Nabil Antaki et al.
LIVER INTERNATIONAL (2010)
Multi-arm clinical trials of new agents: Some design considerations
Boris Freidlin et al.
CLINICAL CANCER RESEARCH (2008)
A predictive probability design for phase II cancer clinical trials
J. Lack Lee et al.
CLINICAL TRIALS (2008)
Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: A tutorial
Sarah Zohar et al.
CONTEMPORARY CLINICAL TRIALS (2008)
Bayesian clinical trials
DA Berry
NATURE REVIEWS DRUG DISCOVERY (2006)
Factorial designs in clinical trials: Options for combination treatment studies
DJ Couper et al.
JOURNAL OF STUDIES ON ALCOHOL (2005)
分享论文
